(Reuters) – French healthcare group Sanofi’s first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.
First-quarter business operating income, or adjusted earnings before interest and tax, rose to 3.07 billion euros ($3.23 billion), surpassing the average analyst estimate of 2.84 billion euros posted on the company’s website.
Sanofi said on Thursday that it still expects 2022 adjusted earnings per share to grow at a low double-digit percentage.
Revenues of eczema and asthma treatment Dupixent jumped over 45% to 1.61 billion euros, beating an analyst consensus of 1.58 billion euros. ($1 = 0.9500 euros)
(Reporting by Ludwig Burger; Editing by Sudip Kar-Gupta)
